Grants Funded
Grant applicants for the 2024 cycle requested a total of nearly $3 million dollars. The PSF Study Section Subcommittees of Basic & Translational Research and Clinical Research evaluated more than 100 grant applications on the following topics:
The PSF awarded research grants totaling over $650,000 dollars to support more than 20 plastic surgery research proposals.
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Research Abstracts
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
Overcoming Skin Immunogenicity in Transplantation Tolerance
Mario Solari MD
2006
University of Pittsburgh
Basic Research Grant
Composite Tissue Allotransplantation
The overall goal of this research project is to perform composite tissue allotransplantation without the use of long-term systemic immunosuppression through induction of tolerance. Special attention will be given to examining the immunogenicity of skin. The focus of our laboratory has been to explore the interactions between the immune system and allogeneic musculoskeletal tissues (skin, muscle, bone, nerve, etc.). Induction of donor-specific tolerance would permit significant advances in reconstructive surgery and bum treatment, where autologous sources of tissue are inadequate or absent. Dendritic cells (DCs) are highly specialized, bone marrow-derived antigen presenting cells (APCs) that induce and regulate immune responses. DCs can be manipulated, either in vivo or in vitro to promote antigen specific tolerance. We hypothesize that pulsing "tolerogeneic" DCs with donor skin antigen in addition to donor major histocompatibility complex (MHC) alloantigens will promote long-term survival of skin as well as the other components of a CTA.
